Posted by Michael Wonder on 14 Jul 2020
Tremfya (guselkumab) approved by U.S. Food and Drug Administration as the first selective interleukin-23 inhibitor for active psoriatic arthritis
14 July 2020 - In two Phase 3 clinical trials, Tremfya significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterised by painful joints and skin inflammation.
Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA.
